High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 4, 2008, Pages 1482-1488

  Anuurad, Erdembileg ^a   Rubin, Jill ^b   Chiem, Alan ^a   Tracy, Russell P ^c   Pearson, Thomas A ^d   Berglund, Lars ^a,e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; C REACTIVE PROTEIN; FIBRINOGEN; LIPOPROTEIN A;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; GENOTYPE; HUMAN; INFLAMMATION; KRINGLE DOMAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 42049104360     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2416     Document Type: Article

References (53)

1. Ross R 1999 Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
2. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V 2004 C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387-1397
3. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A 2005 Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799-1809
4. Bogavac-Stanojevic N, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Spasic S, Kalimanovska-Ostric D 2007 Lipid and inflammatory markers for the prediction of coronary artery disease: a multi-marker approach. Clin Biochem 40:1000-1006
5. D'Angelo A, Ruotolo G, Garancini P, Sampietro F, Mazzola G, Calori G 2006 Lipoprotein (a), fibrinogen and vascular mortality in an elderly northern Italian population. Haematologica 91:1613-1620
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565
7. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH 1998 Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-733
8. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB 1987 Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-1186
9. Cantin B, Despres JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, Bergeron J, Dagenais GR 2002 Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 89:662-666
10. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr SC, Taubert K, Tracy RP, Vinicor F 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
11. Utermann G 1989 The mysteries of lipoprotein (a). Science 246:904-910
12. Stein JH, Rosenson RS 1997 Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 157:1170-1176
13. Danesh J, Collins R, Peto R 2000 Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082-1085
14. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM 1987 cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137
15. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H 1996 Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 37:2569-2585
16. Rubin J, Kim HJ, Pearson TA, Holleran S, Ramakrishnan R, Berglund L 2006 Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a]. J Lipid Res 47:982-989
17. Anuurad E, Lu G, Rubin J, Pearson TA, Berglund L 2007 ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African-Americans: the Harlem-Basset Study. J Lipid Res 48:693-698
18. Marcovina SM, Albers JJ, Jacobs Jr DR, Perkins LL, Lewis CE, Howard BV, Savage P 1993 Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African-Americans. The CARDIA study. Arterioscler Thromb 13:1037-1045
19. Paultre F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L 2000 High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20:2619-2624
20. Chretien JP, Coresh J, Berthier-Schaad Y, Kao WH, Fink NE, Klag MJ, Marcovina SM, Giaculli F, Smith MW 2006 Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African-Americans compared with European Americans. J Med Genet 43:917-923
21. Ramharack R, Barkalow D, Spahr MA 1998 Dominant negative effect of TGF-β1 and TNF-α on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 18:984-990
22. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM 1993 5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci USA 90:1369-1373
23. Anuurad E, Rubin J, Lu G, Pearson TA, Holleran S, Ramakrishnan R, Berglund L 2006 Protective effect of apolipoprotein E2 on coronary artery disease in African-Americans is mediated through lipoprotein cholesterol. J Lipid Res 47:2475-2481
24. Philbin EF, Weil HF, Francis CA, Marx HJ, Jenkins PL, Pearson TA, Reed RG 2000 Race-related differences among patients with left ventricular dysfunction: observations from a biracial angiographic cohort. Harlem-Bassett LP(A) Investigators. J Card Fail 6:187-193
25. Macy EM, Hayes TE, Tracy RP 1997 Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43:52-58
26. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH 1997 Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979
27. Clauss A 1957 [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 17:237-246 (German)
28. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
29. Lackner C, Cohen JC, Hobbs HH 1993 Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 2:933-940
30. Rubin J, Paultre F, Tuck CH, Holleran S, Reed RG, Pearson TA, Thomas CM, Ramakrishnan R, Berglund L 2002 Apolipoprotein [a] genotype influences isoform dominance pattern differently in African-Americans and Caucasians. J Lipid Res 43:234-244
31. Kamboh MI, Ferrell RE, Kottke BA 1991 Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 49:1063-1074
32. Marcovina SM, Hobbs HH, Albers JJ 1996 Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem 42:436-439
33. Mora S, Lee IM, Buring JE, Ridker PM 2006 Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA 295:1412-1419
34. Ridker PM 2003 Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363-369
35. Toss H, Lindahl B, Siegbahn A, Wallentin L 1997 Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96:4204-4210
36. Danesh J, Collins R, Appleby P, Peto R 1998 Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477-1482
37. Wong ND, Pio J, Valencia R, Thakal G 2001 Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III. Prev Cardiol 4:109-114
38. Miller M, Zhan M, Havas S 2005 High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 165:2063-2068
39. Lin SX, Pi-Sunyer EX 2007 Prevalence of the metabolic syndrome among US middle-aged and older adults with and without diabetes: a preliminary analysis of the NHANES 1999-2002 data. Ethn Dis 17:35-39
40. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto Jr AM 1985 Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 5:265-272
41. Parra HJ, Luyeye I, Bouramoue C, Demarquilly C, Fruchart JC 1987 Blackwhite differences in serum Lp(a) lipoprotein levels. Clin Chim Acta 168:27-31
42. Gaubatz JW, Ghanem KI, Guevara Jr J, Nava ML, Patsch W, Morrisett JD 1990 Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res 31:603-613
43. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G 1991 Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 86:607-614
44. Marcovina SM, Kennedy H, Bittolo Bon G, Cazzolato G, Galli C, Casiglia E, Puato M, Pauletto P 1999 Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: The Lugalawa Study. Arterioscler Thromb Vasc Biol 19:1250-1256
45. Kronenberg F, Kathrein H, Konig P, Neyer U, Sturm W, Lhotta K, Grochenig E, Utermann G, Dieplinger H 1994 Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14:1405-1411
46. Mooser V, Berger MM, Tappy L, Cayeux C, Marcovina SM, Darioli R, Nicod P, Chiolero R 2000 Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler Thromb Vasc Biol 20:1137-1142
47. Kargman DE, Tuck C, Berglund L, Lin IF, Mukherjee RS, Thompson EV, Jones J, Boden-Albala B, Paik MC, Sacco RL 1998 Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis 139:391-399
48. Slunga L, Johnson O, Dahlen GH, Eriksson S 1992 Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 52:95-101
49. Noma A, Abe A, Maeda S, Seishima M, Makino K, Yano Y, Shimokawa K 1994 Lp(a): an acute-phase reactant? Chem Phys Lipids 67-68:411-417
50. Shai I, Rimm EB, Hankinson SE, Cannuscio C, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J 2005 Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier? Eur Heart J 26:1633-1639
51. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL 2003 Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41:360-370
52. Paultre F, Tuck CH, Boden-Albala B, Kargman DE, Todd E, Jones J, Paik MC, Sacco RL, Berglund L 2002 Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population. Arterioscler Thromb Vasc Biol 22:141-146
53. Rodriguez C, Pablos-Mendez A, Palmas W, Lantigua R, Mayeux R, Berglund L 2002 Comparison of modifiable determinants of lipids and lipoprotein levels among African-Americans, Hispanics, and non-Hispanic Caucasians ≥65 years of age living in New York City. Am J Cardiol 89:178-183